Page last updated: 2024-12-08
4,4'-dithiobis(phenylazide)
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4,4'-dithiobis(phenylazide): RN given refers to cpd with unspecified locants [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 169921 |
| SCHEMBL ID | 15019835 |
| MeSH ID | M0084617 |
Synonyms (16)
| Synonym |
|---|
| 4-azidophenyl disulfide |
| 4,4'-dithiobis(phenylazide) |
| 37434-06-3 |
| dtbpa |
| disulfide, bis(4-azidophenyl) |
| 4,4'-dithiobis(phenyl azide) |
| FT-0625370 |
| 4,4'-dithiobisphenylazide |
| 4,4'-dithiobis-(phenyleizide) |
| SCHEMBL15019835 |
| DTXSID30190882 |
| dithiobis(phenylazide) |
| mfcd00049054 |
| [[4-[[(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)-lambda4-sulfanylidene]-lambda4-sulfanylidene]cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide |
| 1,2-bis(4-azidophenyl)disulfane |
| YSZCS015 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||